Protein Delivery in Intermittent and Continuous Enteral Nutrition in ICU Patients (ProBoNo)
Primary Purpose
Muscle Wasting in Critically Ill
Status
Recruiting
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Enteral nutrition with Fresubin Intensive
Sponsored by
About this trial
This is an interventional prevention trial for Muscle Wasting in Critically Ill focused on measuring intensive care unit, intermittent enteral nutrition, continuous enteral nutrition, muscle wasting
Eligibility Criteria
Inclusion Criteria:
- Informed Consent as documented by signature
- Adult patients (age 18 years or older)
- Expected ICU stay of five days or longer
- Expected enteral feeding during at least five days
Exclusion Criteria:
- Pregnancy or breast feeding (women of childbearing age are tested for high beta-human chorionic gonadotropin (hCG) in urine or serum upon ICU admission)
- Clinically significant chronic or acute kidney insufficiency with a glomerular filtration rate (GFR) <15.
- BMI ≤ 18 and ≥ 35.
- Intestinal perforation, peritonitis, intestinal fistula, necrosis or other contraindication to enteral diet
- Death or discharge before 48 hours of observation
- Noradrenaline ≥ 0.5 µg/kg bodyweight /min
- Inherited and chronic skeletal muscle disease (e.g. Morbus Duchenne or other motoneuron disease)
- Paralysis (e.g. hemiplegia, tetraplegia and paraplegia)
- Immunosuppression
- Haematologic malignancy
Sites / Locations
- University Hospital Basel, operative ICURecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Bolus enteral nutrition with Fresubin Intensive
Continuous enteral nutrition with Fresubin Intensive
Arm Description
Bolus nutrition over 30-40 minutes every 4 hours with Fresubin Intensive
Continuous nutrition over 20 hours per day with Fresubin Intensive (standard)
Outcomes
Primary Outcome Measures
Daily protein target quantity
Is the time from 6.00 am of the following day after admission until the patient reaches his daily protein target quantity (1.2 g/ kg Biologische Wertigkeit (BW)/ biological value protein in the control group, to 1.5 g/kg BW protein in the experimental group).
Secondary Outcome Measures
Diameter of the hamstrings
Diameter of the hamstrings assessed by ultrasound and histology
Gastric residual content
Amount of gastric residual volume (ml)
Diarrhoea
Number of diarrhoea events
Glucose (mmol/l) measurement
Laboratory parameters relevant to assess under enteral Nutrition (Glucose (mmol/l))
BUN (mg/dl) measurement
Laboratory parameters relevant to assess under enteral Nutrition (BUN (mg/dl))
IGF-1 (mmol/l) measurement
Laboratory parameters relevant to assess under enteral Nutrition (IGF-1 (mmol/l))
Full Information
NCT ID
NCT03587870
First Posted
June 4, 2018
Last Updated
June 5, 2023
Sponsor
University Hospital, Basel, Switzerland
1. Study Identification
Unique Protocol Identification Number
NCT03587870
Brief Title
Protein Delivery in Intermittent and Continuous Enteral Nutrition in ICU Patients
Acronym
ProBoNo
Official Title
Protein Delivery in Intermittent and Continuous Enteral Nutrition in ICU Patients A Prospective, Randomised Controlled Pilot Study in Critical Ill Patients With a Protein-rich Formula
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 25, 2019 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
March 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Basel, Switzerland
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Acute skeletal muscle wasting in ICU patients is associated with functional impairment and with increased risk of death. Of what we know today, physical disability can persist up to 5 years. Adequate nutrition is the basis for an optimal recovery for ICU patients and for prevention of muscle wasting. Today, continuous feeding is still the standard enteral nutrition form for patients in the ICU to limit the incidence of aspiration. A study of Serpa et al. and Georgia et al. compared the continuous feeding versus a bolus nutrition with a feeding time of 30 - 60 minutes every 4 hours. They showed no statistical differences in complications between both groups.
ProBoNo is a prospective, randomized, controlled pilot study of critically ill patients with a protein- rich formula to explore the impact of continuous or intermittent bolus nutrition on muscle breakdown in ICU patients. The investigators would like to recruit 68 patients during the first 24 hours after surgical intensive care unit admission. Prior beginning of nutrition administration, and on the 7th day thereafter the investigators will perform a muscle biopsy and an ultrasound from the vastus lateralis muscle in both groups.
The primary outcome is the time from 6.00 am of the following day after admission until the patient reaches his daily protein's target quantity. Secondary outcomes include the diameter and densitiy of the hamstrings assessed by ultrasound and histology, the process of gastric residual volume, number of diarrhoea events and laboratory findings like glucose, urea and insulin like growth factor (IGF)-1, all compared between the two time points.
Intermittent feeding is not only more natural and could help to limit the muscle wasting in ICU patients, it is also easier to handle for the ICU caring medical team. A trial from Georgia et al. in 2007 compared continuous to intermittent enteral nutrition. They found that the intermittently fed patients reached their nutrition goal faster than those being continuously nourished. This might in part be explained by feeding interruptions in the continuous feeding regimen. Presumably, preoperative holding of tube feedings in the continuous nutrition group most commonly caused interruptions. Thus, independently from prevention of muscle breakdown, a bolus nutrition would be more attractive.
Detailed Description
The relevance of early continuous or intermittent enteral feeding of critically ill patients has been discussed controversially in the last years. Today, continuous feeding is still the standard for enteral nutrition in the ICU. The continuous nutrition can prevent abdominal intolerance like vomiting, diarrhoea and aspiration. Pulmonary aspiration is the most dramatic consequence of enteral nutrition and can be limited by a continuous feeding as shown by a study in 2003. However, nutrition was started with a bolus of 125ml as baseline by force of gravity over 15 minutes. Compared to the continuous nutrition, this is considered much volume in a short time. Naturally, risk of gastric intolerance in this scenario is very high.
In other studies, a similar amount of nutrition was given over a longer period of time (30 - 60 minutes) every 4 hours. In each cohort (continuous and bolus), only one case of pulmonary aspiration or tube obstruction was detected. After this study, other trials with a similar result followed. In 2007 a trial of Georgia et al. showed no statistical differences in complications regarding tube feeding, no differences of diarrhoea, emesis or pneumonias between continuous and bolus nutrition. The feeding time for bolus nutrition is also a critical influential factor. When an intermittent feeding is given over a longer period of time (20-40 minutes), the incidence of nausea and vomiting has not increased.
Intermittent feeding is not only a good alternative to continuous feeding, but also more natural, as long-term intake of nutrition over 20 hours is not common in any mammal. The alimentary tract and metabolic pathways of humans seem designed for intermittent ingestion of essential nutrients reduced to a few times a day. Different hormones of the endocrine cells affect complex roles of gastrointestinal motility, gall bladder contraction and nutrient absorption. The level of these hormones depends on the amount of nutrient ingestion. This response of the hormones is almost completely abolished in continuous feeding. But in intermittent nutrition, hormones like incretin, glucose-dependent insulinotropic polypeptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) boost the level of insulin and the resulting carbohydrate load and therefore influence the muscle protein synthesis and breakdown.
In healthy individuals, the anabolic effects of feeding occur due to an increase on the synthetic rate of muscle protein synthesis of approximately 300% with a simultaneous 50% decrease in the rate of protein breakdown. Two studies of 2009 and 2011 compared the intermittent bolus and continuous feeding and the effect of protein synthesis in skeletal muscle in neonatal pigs. They analysed the fractional rates of protein synthesis in muscle samples of continuous and intermittent bolus feeding groups. They could show that although both groups, continuous and intermittent bolus feeding, stimulate muscle protein synthesis, but in the bolus-fed, in the fractional rates of protein synthesis called K's was greater after a meal.
An ongoing study wants to show the effect of bolus vs. continuous feeding in ICU patients related to muscle wasting by measurements of ultrasound and blood samples. In this trial, the investigators would like to have a similar approach but with different measurements. Using ultrasound and muscle biopsies, the investigators aim to determine whether intermittent enteral feeding could preserve muscle mass better or more than standard continuous enteral feeding in the critically ill patients. In addition, the investigators would like to assess if intermittent bolus feeding optimizes protein intake in the first 7 days of critical illness since the intermittent route is less affected by interruptions following treatment and diagnostic procedures.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Muscle Wasting in Critically Ill
Keywords
intensive care unit, intermittent enteral nutrition, continuous enteral nutrition, muscle wasting
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A prospective, randomised controlled pilot study in critical ill patients with a protein-rich formula
Masking
None (Open Label)
Allocation
Randomized
Enrollment
68 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Bolus enteral nutrition with Fresubin Intensive
Arm Type
Experimental
Arm Description
Bolus nutrition over 30-40 minutes every 4 hours with Fresubin Intensive
Arm Title
Continuous enteral nutrition with Fresubin Intensive
Arm Type
Active Comparator
Arm Description
Continuous nutrition over 20 hours per day with Fresubin Intensive (standard)
Intervention Type
Other
Intervention Name(s)
Enteral nutrition with Fresubin Intensive
Intervention Description
Comparison of intermittent (experimental) vs continuous (standard, active comparator) enteral nutrition on muscle wasting in critically ill patients
Primary Outcome Measure Information:
Title
Daily protein target quantity
Description
Is the time from 6.00 am of the following day after admission until the patient reaches his daily protein target quantity (1.2 g/ kg Biologische Wertigkeit (BW)/ biological value protein in the control group, to 1.5 g/kg BW protein in the experimental group).
Time Frame
During ICU stay for the duration of 7 days after study inclusion
Secondary Outcome Measure Information:
Title
Diameter of the hamstrings
Description
Diameter of the hamstrings assessed by ultrasound and histology
Time Frame
During ICU stay, exactly 7 days after study inclusion
Title
Gastric residual content
Description
Amount of gastric residual volume (ml)
Time Frame
Every day during ICU stay for the duration of 7 days after study inclusion
Title
Diarrhoea
Description
Number of diarrhoea events
Time Frame
Every day during ICU stay for the duration of 7 days after study inclusion
Title
Glucose (mmol/l) measurement
Description
Laboratory parameters relevant to assess under enteral Nutrition (Glucose (mmol/l))
Time Frame
Every day during ICU stay for the duration of 7 days after study inclusion
Title
BUN (mg/dl) measurement
Description
Laboratory parameters relevant to assess under enteral Nutrition (BUN (mg/dl))
Time Frame
Every day during ICU stay for the duration of 7 days after study inclusion
Title
IGF-1 (mmol/l) measurement
Description
Laboratory parameters relevant to assess under enteral Nutrition (IGF-1 (mmol/l))
Time Frame
Every day during ICU stay for the duration of 7 days after study inclusion
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Informed Consent as documented by signature
Adult patients (age 18 years or older)
Expected ICU stay of five days or longer
Expected enteral feeding during at least five days
Exclusion Criteria:
Pregnancy or breast feeding (women of childbearing age are tested for high beta-human chorionic gonadotropin (hCG) in urine or serum upon ICU admission)
Clinically significant chronic or acute kidney insufficiency with a glomerular filtration rate (GFR) <15.
BMI ≤ 18 and ≥ 35.
Intestinal perforation, peritonitis, intestinal fistula, necrosis or other contraindication to enteral diet
Death or discharge before 48 hours of observation
Noradrenaline ≥ 0.5 µg/kg bodyweight /min
Inherited and chronic skeletal muscle disease (e.g. Morbus Duchenne or other motoneuron disease)
Paralysis (e.g. hemiplegia, tetraplegia and paraplegia)
Immunosuppression
Haematologic malignancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alexa Hollinger, MD
Phone
+41786747130
Email
alexa.hollinger@usb.ch
First Name & Middle Initial & Last Name or Official Title & Degree
Désirée Yeginsoy, MD
Phone
+41774261353
Email
desi.y@bluewin.ch
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexa Hollinger, MD
Organizational Affiliation
University Hospital Basel, Basel Switzerland
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Basel, operative ICU
City
Basel
State/Province
Basel-Stadt
ZIP/Postal Code
4031
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexa Hollinger, Dr. MD
12. IPD Sharing Statement
Citations:
PubMed Identifier
32843075
Citation
Reinhold S, Yeginsoy D, Hollinger A, Todorov A, Tintignac L, Sinnreich M, Kiss C, Gebhard CE, Kovacs B, Gysi B, Imwinkelried L, Siegemund M. Protein delivery in intermittent and continuous enteral nutrition with a protein-rich formula in critically ill patients-a protocol for the prospective randomized controlled proof-of-concept Protein Bolus Nutrition (Pro BoNo) study. Trials. 2020 Aug 25;21(1):740. doi: 10.1186/s13063-020-04635-1.
Results Reference
derived
Learn more about this trial
Protein Delivery in Intermittent and Continuous Enteral Nutrition in ICU Patients
We'll reach out to this number within 24 hrs